Bank of America Corp DE Has $364,000 Holdings in Codexis, Inc. (NASDAQ:CDXS)

Bank of America Corp DE raised its holdings in shares of Codexis, Inc. (NASDAQ:CDXS) by 37.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 76,305 shares of the biotechnology company’s stock after purchasing an additional 20,589 shares during the period. Bank of America Corp DE owned 0.09% of Codexis worth $364,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in CDXS. Summit Investment Advisors Inc. lifted its position in Codexis by 81.4% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 3,783 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Codexis by 38.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 31,552 shares of the biotechnology company’s stock valued at $151,000 after purchasing an additional 8,832 shares during the period. Intech Investment Management LLC lifted its position in Codexis by 55.1% during the 4th quarter. Intech Investment Management LLC now owns 33,111 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 11,757 shares during the period. Corebridge Financial Inc. lifted its position in Codexis by 7.2% during the 4th quarter. Corebridge Financial Inc. now owns 40,052 shares of the biotechnology company’s stock valued at $191,000 after purchasing an additional 2,703 shares during the period. Finally, MetLife Investment Management LLC lifted its position in Codexis by 162.4% during the 4th quarter. MetLife Investment Management LLC now owns 46,160 shares of the biotechnology company’s stock valued at $220,000 after purchasing an additional 28,569 shares during the period. 78.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Codexis to a “sell” rating in a research report on Friday, May 16th.

Codexis Stock Performance

Shares of NASDAQ:CDXS opened at $2.25 on Friday. The company has a market capitalization of $186.40 million, a price-to-earnings ratio of -2.59 and a beta of 2.52. The firm’s 50 day simple moving average is $2.33 and its 200 day simple moving average is $3.52. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. Codexis, Inc. has a fifty-two week low of $1.90 and a fifty-two week high of $6.08.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). The firm had revenue of $7.54 million during the quarter, compared to analyst estimates of $10.38 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. As a group, sell-side analysts forecast that Codexis, Inc. will post -0.77 earnings per share for the current year.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.